Gosuke Homma

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

A Cautionary Note on Regional Consistency Evaluation With Multiple Primary Endpoints in Multiregional Clinical Trials.

A Cautionary Note on Regional Consistency Evaluation With Multiple Primary Endpoints in Multiregional Clinical Trials.

Journal: Pharmaceutical statistics
Published: April 13, 2026

Exact power and sample size in clinical trials with two co-primary binary endpoints.

Exact power and sample size in clinical trials with two co-primary binary endpoints.

Journal: Statistical methods in medical research
Published: August 29, 2025

Analytical Evaluation of the 2-in-1 Adaptive Design for Binary Endpoints.

Analytical Evaluation of the 2-in-1 Adaptive Design for Binary Endpoints.

Journal: Statistics in medicine
Published: February 10, 2025

Cautionary note on regional consistency evaluation in multiregional clinical trials with binary outcomes.

Cautionary note on regional consistency evaluation in multiregional clinical trials with binary outcomes.

Journal: Pharmaceutical statistics
Published: August 30, 2023

Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY).

Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY).

Journal: Diabetes, obesity & metabolism
Published: June 23, 2023

Sample size calculation in clinical trials with two co-primary endpoints including overdispersed count and continuous outcomes.

Sample size calculation in clinical trials with two co-primary endpoints including overdispersed count and continuous outcomes.

Journal: Pharmaceutical statistics
Published: February 10, 2023

Usefulness of the placebo lead-in design for clinical trials with binary outcomes.

Usefulness of the placebo lead-in design for clinical trials with binary outcomes.

Journal: Clinical trials (London, England)
Published: January 11, 2023

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset.

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset.

Journal: JTO clinical and research reports
Published: December 22, 2020

Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.

Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.

Journal: Headache
Published: December 10, 2020

Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial.

Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial.

Journal: Clinical drug investigation
Published: October 08, 2020

Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.

Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.

Journal: Cancer science
Published: July 09, 2020

Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.

Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.

Journal: Journal of gastroenterology
Published: October 20, 2019
Showing 1-12 of 15

Last Updated: 09/26/2026